Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones

Posted by Matt Breese on Nov 5, 2015

Find me on:

Touching a network across healthcare in pharma, payer and provider, MMIT's team of experts takes a closer look at growth hormones in our most recent Reality Check. The following highlights some of our key takeaways from the piece.

Payer Coverage: All products in this therapeutic class require prior authorization within top plans. Market access reveals that payer formularies do not cover growth hormone drugs for one-third of pharmacy benefit lives. 

Source: MMIT data as of Q4 2015

Trends: A global report via Pharma Exec predicts that the growth hormone market will reach $1.88 billion by 2024. The introduction of biobetters will seize significant market share from daily recombinant growth hormones. Additionally, manufacturers develop more effective delivery techniques that require less-frequent doses and lead to better outcomes for patients, according to Med Gadget.

Key Findings: MMIT's pharmacists reveal several key findings when taking a closer look at the data for growth hormones. The prevalence of prior authorization criteria dominates the current growth hormone market landscape. Pharmacists believe that this results from the history of off-label usage in the class. Top payers typically identify one or two growth hormone products as preferred treatments. Furthermore, most commercial payers implement comprehensive exclusion lists to block the remaining treatments in the class. Clinical experts expect long-acting treatments to improve patient adherence, enabling emerging pharma to compete with more-established manufacturers.

In the full Reality Check on growth hormones below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

 View Reality Check

Topics: Market Access